We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+27.98%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$300M
AUM Growth
+$102M
Cap. Flow
+$5.36M
Cap. Flow %
1.79%
Top 10 Hldgs %
74.87%
Holding
29
New
7
Increased
5
Reduced
5
Closed
6
Avg Time Held Equity + Options
0.2 years
Top 10 Avg Time Held Equity + Options
0.2 years
Top 20 Avg Time Held Equity + Options
0.2 years
Avg Time Held Equity only
0.2 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.2 years

Top Buys

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$32.6M
2
ATRA icon
Atara Biotherapeutics
ATRA
+$17.9M
3
DCOY icon
Decoy Therapeutics
DCOY
+$15.5M
4
ASMB icon
Assembly Biosciences
ASMB
+$6.36M
5
TVTX icon
Travere Therapeutics
TVTX
+$6.25M

Top Sells

Rank Stock Value
1
SAGE icon
Sage Therapeutics
SAGE
+$16.3M
2
MGNX icon
MacroGenics
MGNX
+$15.9M
3
KITE
Kite Pharma, Inc.
KITE
+$10.5M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$9.98M
5
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$3.44M

Sector Composition

Rank Sector Weight
1 Healthcare 73.61%
2 Miscellaneous 26.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
KERX
26
CALL
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-589,000
Closed -$8.33M –
VTAE
27
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
– –
-207,000
Closed -$3.44M –
OMED
28
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
– –
-157,038
Closed -$3.42M –
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2015 Portfolio in Review

As of Q1 2015, EcoR1 Capital held 29 positions worth $300M, up 52% from $198M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

EcoR1 Capital's Q1 2015 filing shows 7 new, 5 increased, 5 reduced and 6 closed positions. Its largest new stake was Epizyme, Inc: 1,580,400 shares worth $29.7M. The largest sale was Sage Therapeutics, an estimated $16.3M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 75% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q1 2015 buy was Epizyme, Inc: 1,580,400 shares worth $29.7M.
  • EcoR1 Capital added most to Atara Biotherapeutics in Q1 2015, an estimated $17.9M increase.
  • EcoR1 Capital's biggest Q1 2015 reduction was Sage Therapeutics, cutting an estimated $16.3M.
  • EcoR1 Capital fully exited MacroGenics in Q1 2015, selling an estimated $15.9M.
  • EcoR1 Capital's ten largest holdings make up 75% of its $300M portfolio in Q1 2015.
  • EcoR1 Capital opened 7 new positions and closed 6 in Q1 2015.
  • EcoR1 Capital's portfolio value rose 52% quarter-over-quarter to $300M.

Based on EcoR1 Capital's 13F filing for Q1 2015, filed 15 May 2015.